Publications by authors named "Vincent A DiPippo"

Claim this Profile
I
Impact of Concomitant Hormone Therapy on the Diagnostic Performance of F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B.
Lawrence Saperstein, Steven P Rowe, Michael A Gorin, Kenneth J Pienta, Barry A Siegel, Vincent A DiPippo

Prostate· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial.
Meera R Chappidi, Amir Iravani, Nancy Stambler, Saradha Baskaran, Vincent A DiPippo

Clin Genitourin Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
Camilo Jimenez, Bennett B Chin, Richard B Noto, Joseph S Dillon, Lilja Solnes, Vincent A DiPippo

Endocr Relat Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Daniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, Mark T Fleming, David C Smith, Vincent A DiPippo

Prostate· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of High-Specific-Activity I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.
Daniel A Pryma, Bennett B Chin, Richard B Noto, Joseph S Dillon, Stephanie Perkins, Vincent A DiPippo

J Nucl Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Daniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, Anthony Mega, Mark T Fleming, Vincent A DiPippo

Prostate· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.
Vincent A DiPippo, Holly M Nguyen, Lisha G Brown, William C Olson, Robert L Vessella

Prostate· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
Jose D Murga, Sameer M Moorji, Amy Q Han, Wells W Magargal, Vincent A DiPippo

Prostate· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
Vincent A DiPippo, William C Olson, Holly M Nguyen, Lisha G Brown, Robert L Vessella

Prostate· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis